Other languages Egetis Therapeutics AB

Equities

EGTX

SE0003815604

Market Closed - Nasdaq Stockholm Other stock markets 08:59:47 06/05/2024 pm IST			5-day change	1st Jan Change
6.11 ^SEK	-5.56%		+4.09%	+9.50%

03/05	Egetis Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
22/02	Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Egetis Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05
Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02
Egetis Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
Egetis Therapeutics AB Appoints Laetitia Szaller as General Counsel and Head of Compliance	22/12
Egetis Therapeutics AB Provides Update on Disease Awareness and the Expanded Access Program for Tiratricol in the USA	13/12
Egetis Therapeutics Grants Fujimoto Pharmaceutical Exclusive Rights to Emcitate in Japan; Stock Rises	10/11
Egetis Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Egetis Therapeutics' Marketing Authorization Application for Emcitate Validated in EU	27/23/27
Egetis Therapeutics AB Announces Ema Validation of Marketing Authorisation Application for Emcitate for the Treatment of Mct8 Deficiency	27/23/27
Egetis Therapeutics AB Submits Marketing Authorisation Application for Emcitate for Treatment of MCT8 Deficiency to the European Medicines Agency	09/23/09
Egetis Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	22/23/22
Egetis Therapeutics AB Announces First Patient Included and Second Site Activated in the Pivotal Retriact Trial	24/23/24
Egetis Therapeutics AB Announces Site Activation in the Pivotal Retriact Trial for Emcitate	29/23/29
Egetis Terminates Discussions Regarding Potential Acquisition	24/23/24
Egetis Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2023	26/23/26
Egetis Comments on M&A Rumors	30/23/30
Egetis Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2022	22/23/22
Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	22/23/22
Egetis Therapeutics AB Appoints Katayoun Welin-Berger as Vice President Operations, Effective from March 2023	27/23/27
Egetis Therapeutics AB Announces Executive Changes	20/22/20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Egetis Therapeutics AB

Equities

EGTX

SE0003815604

Other languages

Filters